To investigate the potential of phosphorylated tau as a blood-based biomarker for diagnosing systemic amyloidosis.
Key Findings:
p-tau181 levels were higher in patients with AL or ATTR amyloidosis compared to controls.
p-tau181 demonstrated moderate diagnostic discrimination with an AUC of 0.82.
Elevated p-tau181 levels were associated with amyloidosis-related neuropathy.
p-tau217 also showed elevation in amyloidosis patients, distinguishing them from controls.
p-tau181 levels increased in asymptomatic individuals with pathogenic ATTR variants as they approached predicted disease onset.
Interpretation:
Circulating phosphorylated tau may serve as a valuable diagnostic tool for systemic amyloidosis, particularly in differentiating amyloid-related neuropathy from other conditions.
Limitations:
Further studies are needed to validate the findings and integrate biomarkers into diagnostic workflows.
The study was conducted in specific cohorts, which may limit generalizability.
Conclusion:
Phosphorylated tau has potential diagnostic value in systemic amyloidosis and warrants further investigation.
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
